the Effect of Different Mechanical Ventilation Modes on Optic Nerve Diameter and Conscious Functions
The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bursa, Turkey, 60160
- University of Health Sciences Bursa Yuksek Ihtisas Training and Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ASA I-II
- 18-65 years old
Exclusion Criteria:
- Unable to cooperate
- Presence of eye disease (detachment, retinapathy, glaucoma)
- Presence of a previous eye operation
- Those with symptoms of KIBAS (intracranial pressure increase syndrome) (Intracranial lesion, previous cerebrovascular diseases)
- BMI (body mass index> 40 kg / m2
- Obstructive and restrictive lung disease
- Pulmonary Hypertension
- Congestive Heart Failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Pressure controlled ventilation, Volum controlled ventilation
Undergoing laparoscopic cholecystectomy surgery according to mechanical ventilator mode; Group P (n: 30) Pressure controlled ventilation was randomly divided into Group V (n: 30) volume controlled ventilation settings were adjusted to be 50% O2- 50% air, 8ml / kg TV (tidal volume) and PEEP 5.
|
The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations
|
|
Active Comparator: Optic Nerve Sheath Diameter
In optic nerve diameter measurements; A layer of water-soluble sterile gel was applied to the closed upper eyelid.
The linear 10-5 MHz ultrasound probe was carefully placed on the upper eyelid over the gel.
The entrance of the optic nerve to the orbital globe in 2D mode was displayed on the monitor without applying too much pressure.
After finding the optimal contrast between the retrobulbar echogenic fat tissue and vertical hypoechoic band 23, the diameter of the optic nerve sheath was measured 3 mm behind the optic disc using an electronic caliper.
|
The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Optic nerve sheath diameter (milimeter)
Time Frame: 2 hours operation time
|
Optic nerve sheath diameter; It was measured from the optic nerve sheath 3 mm behind the optic disc from the closed upper eyelid.
T0: Awake, T1: 5th minute after induction, T2: Gas insufflation start in supine position, T3: Maximum gas pressure is reached in reverse trendelenburg position, T4: Before extubation in supine position.
A typical optic nerve sheath is generally less than 5 mm in diameter and diameters greater than 5.5 mm predict an ICP of >20 cmH2O .
|
2 hours operation time
|
|
Cognitive Function
Time Frame: 3 months after surgery
|
Cognitive function test with Mini Mental Conditioning Scale was performed to the patients before the anesthesia induction and 3 months after the surgery .
Mini Mental Scale points are between 0 and 30.
|
3 months after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peroperative Complications
Time Frame: 2 hours operation time
|
Complications during the surgery (hypercapnia, hypotension,hypertension,rythm disorder) were recorded.
|
2 hours operation time
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Tugba Onur, MD, BYIEAH
- Study Chair: Korgun Okmen, MD, BYIEAH
- Study Chair: Serkan Terkancıoglu, MD, BYIEAH
- Study Chair: Gorkem Cevik, MD, BYIEAH
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2017-17/23
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.